ClinicalTrials.gg
CompletedNCT03766581AXIOMATIC-SSPUpdated Jun 12, 2023Results posted

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

A Phase 2 interventional study of BMS-986177 and Placebo in Acute Ischemic Stroke and Transient Ischemic Attack (TIA), sponsored by Bristol-Myers Squibb. Completed at 424 sites in 29 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-06-12.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2,366
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 480 studies in Ischemic Stroke with a site in United States — 122 open to participants now, 146 under way, 13 of them phase 3. Ischemic Stroke · United States.

Enrollment
12th of 364
2,366 · median 66
Started
2019
with 24 others
Phase 2
71 of 480
8 open now
Registered
229th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 12th largest by enrollment of the 364 interventional ones that give a count, is one of 25 that started in 2019, is one of 71 in phase 2, and was the 229th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

122 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.

03

Conditions studied

  • Acute Ischemic Stroke
  • Transient Ischemic Attack (TIA)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female ≥40 years of age
  • Acute Ischemic Stroke or
  • Intracranial or Extracranial Atherosclerotic Plaque proximal to the affected brain area

Exclusion criteria

Exclusion Criteria:

  • Predicted inability to swallow study medication
  • Any condition that, in the opinion of the Investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding
  • Use of thrombolytic therapy or mechanical thrombectomy for treatment of index stroke

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,366 participants (actual)

Study arms

  • Placebo comparator
    BMS-986177 Placebo

    Specified Dose on Specified Days

    Other: Placebo · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    Dose 1: BMS-986177 + Aspirin + Clopidogrel

    Specified Dose on Specified Days

    Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    Dose 2: BMS-986177 + Aspirin + Clopidogrel

    Specified Dose on Specified Days

    Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    Dose 3: BMS-986177 + Aspirin + Clopidogrel

    Specified Dose on Specified Days

    Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    Dose 4: BMS-986177 + Aspirin + Clopidogrel

    Specified Dose on Specified Days

    Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    Dose 5: BMS-986177 + Aspirin + Clopidogrel

    Specified Dose on Specified Days

    Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    Dose 6: BMS-986177 + Aspirin + Clopidogrel

    Specified Dose on Specified Days

    Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin

  • Experimental
    Dose 7: BMS-986177 + Aspirin + Clopidogrel

    Specified Dose on Specified Days

    Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90

    Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).

    Time frame: From randomization to up to 90 days after randomization

Secondary outcomes

  1. Percent of Participants With Major Bleeding According to BARC Type 3 and 5

    Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types: 3a = Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding

    Time frame: From first dose to up to 107 days after first dose

  2. Number of Participants With Bleeding Based on BARC Types 1-5

    Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.

    Time frame: From first dose to up to 107 days after first dose

  3. Number of Participants With Bleeding Based on ISTH-Defined Criteria

    Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.

    Time frame: From first dose to up to 107 days after first dose

  4. Number of Participants With Bleeding Based on PLATO-Defined Criteria

    Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions: 1. Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin \>5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs) 2. Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs 3. Any Major: Any one of the above criteria 4. Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention

    Time frame: From first dose to up to 107 days after first dose

  5. Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90

    Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.

    Time frame: From randomization to up to 90 days after randomization

  6. Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death

    Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.

    Time frame: From randomization to up to 90 days after randomization

  7. National Institutes of Health Stroke Scale (NIHSS)

    The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.

    Time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event

  8. Modified Rankin Scale (mRS)

    The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6. 0 = No symptoms at all 1. = No significant disability despite symptoms; able to carry out all usual duties and activities 2. = Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. = Moderate disability; requiring some help, but able to walk without assistance 4. = Moderately severe disability; unable to walk and attend to bodily needs without assistance 5. = Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. = Dead

    Time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event

  9. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of: * ≥26 points: indicates normal cognitive function * 18-25 points: Mild cognitive impairment * 10-17 points: Moderate cognitive impairment * fewer than 10 points: Severe cognitive impairment

    Time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event

  10. Digit Symbol Substitution Test (DSST)

    The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.

    Time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event

  11. Number of Participants With Adverse Events (AEs)

    AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.

    Time frame: From first dose to 2 days after last dose of study therapy (up to approximately 107 days)

  12. Number of Participants With Clinically Significant Vital Sign Abnormalities

    Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.

    Time frame: From first dose to up to 90 days after first dose

  13. Number of Participants With Clinically Significant Physical Examination Abnormalities

    Number of participants with clinically significant physical examination abnormalities.

    Time frame: From first dose to up to 90 days after first dose

  14. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Number of participants with clinically significant ECG abnormalities.

    Time frame: From first dose to up to 90 days after first dose

  15. Number of Participants With Clinically Significant Laboratory Abnormalities - Liver

    The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study. Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)

    Time frame: From first dose to up to approximately 38 months

  16. Percent Change From Baseline in aPTT Activity

    Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.

    Time frame: Baseline and day 90

  17. Percent Change From Baseline in Factor XI Clotting Activity

    Percent change from baseline in factor XI clotting activity via exposure response.

    Time frame: Baseline and day 90

  18. Pharmacokinetic Parameter - Estimated Clearance (CL)

    Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.

    Time frame: From first dose to up to 90 days after first dose

  19. Pharmacokinetic Parameter - Volume of the Central Compartment (VC)

    Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.

    Time frame: From first dose to up to 90 days after first dose

  20. Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI

    Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.

    Time frame: At day 90

  21. Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI

    Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.

    Time frame: At day 90

Other outcomes

  1. Percent of Participants With Ischemic Stroke Events

    Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.

    Time frame: From randomization to up to 90 days after randomization

07

Results

Posted Jun 12, 2023

Participant flow

Randomization
Participant flow — Randomization
MilestonePlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Started6913283183283103512218
Completed6823243133253063452217
Not completed94534601
Withdrew: Other reasons21010000
Withdrew: Participant no longer meets study criteria53402301
Withdrew: Participant request to discontinue study treatment10001200
Withdrew: Participant withdrew consent10121100
Treatment
Participant flow — Treatment
MilestonePlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Started6823253133253063442217
Completed5292602422512302401514
Not completed1536571747610473
Withdrew: Adverse event82444746507752
Withdrew: Participant request to discontinue treatment3461010141501
Withdrew: Participant withdrew consent114554400
Withdrew: Death10000000
Withdrew: Lost to follow-up10010000
Withdrew: Poor/non compliance22111100
Withdrew: Participant no longer meets study criteria91544420
Withdrew: Other reasons138373300

Outcome measures

PrimaryPercent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90

Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).

Time frame:
From randomization to up to 90 days after randomization
Reported as:
Number · Percentage of participants
Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
Percentage of participantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BID
Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 9016.8 (14.2 to 19.4)16.7 (14.4 to 19.0)16.6 (14.5 to 18.7)15.6 (13.6 to 17.9)15.4 (13.0 to 18.0)15.3 (12.3 to 20.4)
Statistical analysis
  • Placebo vs Milvexian 25 mg QD · MCP-MOD · Relative risk (rr): 0.99 · 95% CI 0.87 to 1.1095% confidence interval (CI) for composite event based on bootstrap (10000 samples)
  • Placebo vs Milvexian 25 mg BID · MCP-MOD · Relative risk (rr): 0.99 · 95% CI 0.83 to 1.1595% confidence interval (CI) for composite event based on bootstrap (10000 samples)
  • Placebo vs Milvexian 50 mg BID · MCP-MOD · Relative risk (rr): 0.93 · 95% CI 0.76 to 1.1695% confidence interval (CI) for composite event based on bootstrap (10000 samples)
  • Placebo vs Milvexian 100 mg BID · MCP-MOD · Relative risk (rr): 0.92 · 95% CI 0.73 to 1.1895% confidence interval (CI) for composite event based on bootstrap (10000 samples)
  • Placebo vs Milvexian 200 mg BID · MCP-MOD · Relative risk (rr): 0.91 · 95% CI 0.69 to 1.3195% confidence interval (CI) for composite event based on bootstrap (10000 samples)
SecondaryPercent of Participants With Major Bleeding According to BARC Type 3 and 5

Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types: 3a = Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding

Time frame:
From first dose to up to 107 days after first dose
Reported as:
Number · Percentage of participants
Percent of Participants With Major Bleeding According to BARC Type 3 and 5
Percentage of participantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Percent of Participants With Major Bleeding According to BARC Type 3 and 50.6 (0.2 to 1.5)0.6 (0.1 to 2.2)0.6 (0.1 to 2.3)1.5 (0.5 to 3.6)1.6 (0.5 to 3.8)1.5 (0.5 to 3.4)0 (0 to 15.4)0 (0 to 19.5)
SecondaryNumber of Participants With Bleeding Based on BARC Types 1-5

Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.

Time frame:
From first dose to up to 107 days after first dose
Reported as:
Count of participants · Participants
Number of Participants With Bleeding Based on BARC Types 1-5
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Type 141261628252252
Type 2979710811
Type 3A21112300
Type 3B01113100
Type 3C20030100
Type 400000000
Type 5A00000000
Type 5B00000000
SecondaryNumber of Participants With Bleeding Based on ISTH-Defined Criteria

Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.

Time frame:
From first dose to up to 107 days after first dose
Reported as:
Count of participants · Participants
Number of Participants With Bleeding Based on ISTH-Defined Criteria
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Major42256500
Clinically Relevant Non-Major (CRNM)78978811
Major or CRNM11101112141311
Minor Bleed43251628262252
SecondaryNumber of Participants With Bleeding Based on PLATO-Defined Criteria

Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions: 1. Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin \>5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs) 2. Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs 3. Any Major: Any one of the above criteria 4. Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention

Time frame:
From first dose to up to 107 days after first dose
Reported as:
Count of participants · Participants
Number of Participants With Bleeding Based on PLATO-Defined Criteria
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
MAJOR LIFE-THREATENING21143200
OTHER MAJOR BLEEDING21112300
ANY MAJOR42255500
MINOR76779901
MINIMAL43271828262162
SecondaryPercent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90

Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.

Time frame:
From randomization to up to 90 days after randomization
Reported as:
Number · Percentage of participants
Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
Percentage of participantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 9016.616.218.514.114.816.419.018.8
SecondaryComposite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death

Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.

Time frame:
From randomization to up to 90 days after randomization
Reported as:
Number · Percentage of participants
Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death
Percentage of participantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death6.1 (4.3 to 7.9)5.2 (2.8 to 7.6)4.7 (2.4 to 7.0)4.9 (2.5 to 7.2)5.2 (2.7 to 7.6)9.4 (6.3 to 12.5)18.2 (2.1 to 34.3)5.6 (0 to 16.1)
SecondaryNational Institutes of Health Stroke Scale (NIHSS)

The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.

Time frame:
At baseline, on Days 21 and 90, and at the time of a new stroke event
Reported as:
Mean · Score on a scale
National Institutes of Health Stroke Scale (NIHSS)
Score on a scalePlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Baseline1.6 ± 1.871.7 ± 1.681.6 ± 1.731.6 ± 1.791.8 ± 1.811.6 ± 1.791.1 ± 1.442.0 ± 1.70
Day 210.9 ± 2.110.8 ± 1.350.8 ± 1.430.8 ± 1.580.8 ± 1.480.9 ± 1.880.8 ± 1.900.9 ± 1.39
Day 900.5 ± 1.400.6 ± 1.060.6 ± 1.510.6 ± 1.140.6 ± 1.320.6 ± 1.290.3 ± 0.720.6 ± 1.45
First recurrent stroke6.2 ± 5.014.6 ± 6.795.4 ± 3.174.6 ± 4.307.1 ± 4.684.4 ± 4.605.3 ± 3.061.0 ± NA
SecondaryModified Rankin Scale (mRS)

The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6. 0 = No symptoms at all 1. = No significant disability despite symptoms; able to carry out all usual duties and activities 2. = Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. = Moderate disability; requiring some help, but able to walk without assistance 4. = Moderately severe disability; unable to walk and attend to bodily needs without assistance 5. = Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. = Dead

Time frame:
At baseline, on Days 21 and 90, and at the time of a new stroke event
Reported as:
Mean · Score on a scale
Modified Rankin Scale (mRS)
Score on a scalePlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Baseline0.5 ± 0.870.6 ± 0.950.6 ± 0.960.5 ± 0.860.5 ± 0.890.6 ± 0.950.2 ± 0.530.7 ± 0.99
Day 211.0 ± 1.181.0 ± 1.130.9 ± 1.150.9 ± 1.151.0 ± 1.170.9 ± 1.190.9 ± 1.271.3 ± 1.14
Day 900.7 ± 1.040.8 ± 1.040.8 ± 1.070.7 ± 1.010.7 ± 1.010.8 ± 1.050.6 ± 1.051.0 ± 1.11
First recurrent stroke3.0 ± 1.602.7 ± 1.032.6 ± 1.352.3 ± 1.622.9 ± 1.641.8 ± 1.722.0 ± 0.001.0 ± NA
SecondaryMontreal Cognitive Assessment (MoCA)

The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of: * ≥26 points: indicates normal cognitive function * 18-25 points: Mild cognitive impairment * 10-17 points: Moderate cognitive impairment * fewer than 10 points: Severe cognitive impairment

Time frame:
At baseline, on Days 21 and 90, and at the time of a new stroke event
Reported as:
Mean · Score on a scale
Montreal Cognitive Assessment (MoCA)
Score on a scalePlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Baseline22.3 ± 5.0621.6 ± 5.5922.0 ± 5.1822.5 ± 4.8222.4 ± 5.0422.1 ± 5.3124.4 ± 3.8422.0 ± 4.59
Day 2124.0 ± 4.7723.9 ± 5.0124.0 ± 4.7024.3 ± 4.5723.6 ± 4.4824.0 ± 4.9626.4 ± 2.6124.1 ± 4.70
Day 9024.6 ± 4.5424.0 ± 4.6924.2 ± 4.8024.4 ± 4.4824.5 ± 4.3624.2 ± 5.0525.0 ± 4.7226.4 ± 1.69
First recurrent stroke23.2 ± 6.6317.3 ± 6.1125.3 ± 2.3119.0 ± 8.493.0 ± NA23.1 ± 7.0811.0 ± NA22.0 ± NA
SecondaryDigit Symbol Substitution Test (DSST)

The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.

Time frame:
At baseline, on Days 21 and 90, and at the time of a new stroke event
Reported as:
Mean · Score on a scale
Digit Symbol Substitution Test (DSST)
Score on a scalePlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Baseline34.9 ± 22.3631.2 ± 18.8732.9 ± 22.8937.2 ± 25.6733.7 ± 21.8931.7 ± 19.1547.1 ± 29.3429.2 ± 18.16
Day 2141.2 ± 22.1438.9 ± 19.2740.2 ± 21.6045.1 ± 25.7741.2 ± 22.8739.1 ± 21.3554.6 ± 32.7337.1 ± 20.13
Day 9042.8 ± 21.1841.7 ± 21.6641.3 ± 20.2945.2 ± 21.8645.5 ± 23.4441.4 ± 21.9747.5 ± 27.4840.7 ± 17.46
First recurrent stroke36.3 ± 13.5628.0 ± 20.9542.0 ± 4.3640.5 ± 2.1223.0 ± NA27.5 ± 16.969.0 ± NA47.0 ± NA
SecondaryNumber of Participants With Adverse Events (AEs)

AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.

Time frame:
From first dose to 2 days after last dose of study therapy (up to approximately 107 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Number of Participants With Adverse Events (AEs)3991901861921932111113
SecondaryNumber of Participants With Clinically Significant Vital Sign Abnormalities

Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.

Time frame:
From first dose to up to 90 days after first dose
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Abnormalities
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Number of Participants With Clinically Significant Vital Sign Abnormalities00000000
SecondaryNumber of Participants With Clinically Significant Physical Examination Abnormalities

Number of participants with clinically significant physical examination abnormalities.

Time frame:
From first dose to up to 90 days after first dose
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Physical Examination Abnormalities
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Number of Participants With Clinically Significant Physical Examination Abnormalities00000000
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

Number of participants with clinically significant ECG abnormalities.

Time frame:
From first dose to up to 90 days after first dose
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities00000000
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities - Liver

The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study. Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)

Time frame:
From first dose to up to approximately 38 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities - Liver
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
ALT > 3x ULN42023300
ALT > 5x ULN10002200
ALT > 10x ULN10001100
ALT > 20x ULN00001000
AST > 3x ULN65143310
AST > 5x ULN32102110
AST > 10x ULN10001000
AST > 20x ULN00001000
ALP > 2x ULN45164200
Total Bilirubin > 1.5x ULN106275200
Total Bilirubin > 2x ULN31122100
Concurrent ALT/AST Elevation > 3x ULN with total bilirubin >2x ULN00001000
SecondaryPercent Change From Baseline in aPTT Activity

Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.

Time frame:
Baseline and day 90
Reported as:
Mean · Percent change
Percent Change From Baseline in aPTT Activity
Percent changePlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Percent Change From Baseline in aPTT Activity2.47 ± 0.76838.72 ± 2.26458.30 ± 3.19597.32 ± 3.601140.76 ± 5.154193.64 ± 7.04148.48 ± 11.243118.06 ± 13.840
SecondaryPercent Change From Baseline in Factor XI Clotting Activity

Percent change from baseline in factor XI clotting activity via exposure response.

Time frame:
Baseline and day 90
Reported as:
Mean · Percent change
Percent Change From Baseline in Factor XI Clotting Activity
Percent changePlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Percent Change From Baseline in Factor XI Clotting Activity4.48 ± 3.455-8.88 ± 1.280-17.67 ± 1.900-37.20 ± 1.655-61.52 ± 1.869-70.25 ± 3.0433.86 ± 13.754-44.27 ± 6.501
SecondaryPharmacokinetic Parameter - Estimated Clearance (CL)

Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.

Time frame:
From first dose to up to 90 days after first dose
Reported as:
Geometric mean · L/h
Pharmacokinetic Parameter - Estimated Clearance (CL)
L/hMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BID
Pharmacokinetic Parameter - Estimated Clearance (CL)8.15 ± 348.01 ± 34.37.54 ± 32.87.08 ± 31.37.43 ± 32.9
SecondaryPharmacokinetic Parameter - Volume of the Central Compartment (VC)

Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.

Time frame:
From first dose to up to 90 days after first dose
Reported as:
Geometric mean · L
Pharmacokinetic Parameter - Volume of the Central Compartment (VC)
LMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BID
Pharmacokinetic Parameter - Volume of the Central Compartment (VC)34.9 ± 15231.4 ± 13830.9 ± 14528.9 ± 14931.6 ± 181
SecondaryVolume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI

Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.

Time frame:
At day 90
Reported as:
Mean · mL
Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI
mLPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI2.3492 ± 11.409060.8976 ± 1.963422.9902 ± 8.289931.2682 ± 2.724521.4727 ± 3.787951.2711 ± 4.050358.8960 ± 13.852941.4503 ± 1.89112
SecondaryNumber of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI

Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.

Time frame:
At day 90
Reported as:
Count of participants · Participants
Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI
ParticipantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
>082404936353533
157263626242312
2118553620
385412200
411232201
510001200
>540213000
Other pre-specifiedPercent of Participants With Ischemic Stroke Events

Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.

Time frame:
From randomization to up to 90 days after randomization
Reported as:
Number · Percentage of participants
Percent of Participants With Ischemic Stroke Events
Percentage of participantsPlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QD
Ischemic stroke5.5 (3.8 to 7.2)4.6 (2.3 to 6.8)3.8 (1.7 to 5.9)4.0 (1.9 to 6.1)3.5 (1.5 to 5.6)7.7 (4.9 to 10.5)13.6 (0.0 to 28.0)5.6 (0.0 to 16.1)
Undetermined stroke0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
Statistical analysis
  • Placebo vs Milvexian 25 mg QD · Wald Confidence Limits · Relative risk (rr): 0.83 · 95% CI 0.46 to 1.4995% CIs for RR are constructed using Wald Confidence Limits
  • Placebo vs Milvexian 25 mg BID · Wald Confidence Limits · Relative risk (rr): 0.69 · 95% CI 0.36 to 1.3095% CIs for RR are constructed using Wald Confidence Limits
  • Placebo vs Milvexian 50 mg BID · Wald Confidence Limits · Relative risk (rr): 0.72 · 95% CI 0.39 to 1.3395% CIs for RR are constructed using Wald Confidence Limits
  • Placebo vs Milvexian 100 mg BID · Wald Confidence Limits · Relative risk (rr): 0.65 · 95% CI 0.33 to 1.2595% CIs for RR are constructed using Wald Confidence Limits
  • Placebo vs Milvexian 200 mg BID · Wald Confidence Limits · Relative risk (rr): 1.40 · 95% CI 0.87 to 2.2595% CIs for RR are constructed using Wald Confidence Limits
  • Placebo vs Milvexian 50 mg QD · Wald Confidence Limits · Relative risk (rr): 2.48 · 95% CI 0.83 to 7.4295% CIs for RR are constructed using Wald Confidence Limits
  • Placebo vs Milvexian 100 mg QD · Wald Confidence Limits · Relative risk (rr): 1.01 · 95% CI 0.15 to 6.9695% CIs for RR are constructed using Wald Confidence Limits

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization until their study completion (up to approximately 38 months). SAEs and Other AEs were assessed from first dose to 7 days after last dose of study therapy (up to approximately 112 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo5/691 (0.7%)94/682 (13.8%)178/682 (26.1%)
Milvexian 25 mg QD4/328 (1.2%)37/325 (11.4%)81/325 (24.9%)
Milvexian 50 mg QD0/22 (0%)5/22 (22.7%)6/22 (27.3%)
Milvexian 100 mg QD0/18 (0%)3/17 (17.6%)11/17 (64.7%)
Milvexian 25 mg BID3/318 (0.9%)39/313 (12.5%)83/313 (26.5%)
Milvexian 50 mg BID3/328 (0.9%)41/325 (12.6%)92/325 (28.3%)
Milvexian 100 mg BID5/310 (1.6%)42/306 (13.7%)82/306 (26.8%)
Milvexian 200 mg BID5/351 (1.4%)54/344 (15.7%)90/344 (26.2%)
Most frequent serious events
Showing 10 of 169
Most frequent serious events
EventPlaceboMilvexian 25 mg QDMilvexian 50 mg QDMilvexian 100 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BID
Ischaemic strokeNervous system disorders21/6829/3253/221/176/31310/3257/30611/344
Basilar migraineNervous system disorders0/6820/3250/221/170/3130/3250/3060/344
Stroke in evolutionNervous system disorders5/6822/3250/221/174/3131/3251/3068/344
Acute myocardial infarctionCardiac disorders2/6820/3251/220/170/3130/3250/3061/344
PneumoniaInfections and infestations3/6820/3251/220/170/3131/3252/3061/344
Toxic epidermal necrolysisSkin and subcutaneous tissue disorders0/6820/3251/220/170/3130/3250/3060/344
Urinary tract infectionInfections and infestations1/6822/3250/220/170/3131/3250/3065/344
Transient ischaemic attackNervous system disorders8/6821/3250/220/174/3131/3254/3064/344
Acute kidney injuryRenal and urinary disorders3/6820/3250/220/170/3131/3250/3064/344
Atrial fibrillationCardiac disorders4/6823/3250/220/171/3130/3253/3060/344
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPlaceboMilvexian 25 mg QDMilvexian 50 mg QDMilvexian 100 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BID
ConstipationGastrointestinal disorders44/68222/3250/223/1717/31320/32520/30624/344
HeadacheNervous system disorders23/68216/3253/221/1712/31314/32512/3069/344
AnaemiaBlood and lymphatic system disorders4/6821/3250/222/172/3132/3255/3068/344
NauseaGastrointestinal disorders14/68211/3251/222/176/3136/32511/3065/344
FatigueGeneral disorders6/6822/3250/222/173/3131/3252/3064/344
ParaesthesiaNervous system disorders3/6820/3251/222/170/3130/3251/3061/344
Acute kidney injuryRenal and urinary disorders2/6820/3250/222/171/3131/3251/3069/344
HypertensionVascular disorders56/68221/3250/222/1723/31324/32520/30619/344
Rectal haemorrhageGastrointestinal disorders1/6820/3252/221/170/3131/3251/3062/344
EpistaxisRespiratory, thoracic and mediastinal disorders10/6822/3252/220/174/3135/3254/3066/344

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QDTotal
Mean69.1 ± 10.5870.9 ± 10.6670.1 ± 11.3469.3 ± 10.6969.7 ± 10.5969.5 ± 11.1165.7 ± 10.6465.4 ± 11.6569.6 ± 10.81
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QDTotal
Female254109118121112128710859
Male4372192002071982231581507
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QDTotal
Hispanic or Latino10421211122
Not Hispanic or Latino62202223292777197
Unknown or Not Reported61930429430427932314102147
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboMilvexian 25 mg QDMilvexian 25 mg BIDMilvexian 50 mg BIDMilvexian 100 mg BIDMilvexian 200 mg BIDMilvexian 50 mg QDMilvexian 100 mg QDTotal
White54925724626025128818151884
Black or African American15568353348
Asian35122113111700109
Native Hawaiian or Other Pacific Islander011000002
Asian Indian212100006
Chinese000010001
Japanese84464041394000290
Malay100000001
Asian Other000100001
Other5624511024
08

Study locations

424 sites
  • Local Institution - 0029
    Birmingham, Alabama 35233, United States
  • Local Institution - 0007
    Glendale, California 91206, United States
  • Local Institution - 0006
    Long Beach, California 90806, United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • Local Institution - 0231
    Los Angeles, California 90095, United States
  • Local Institution - 0376
    Sacramento, California 95817, United States
  • Local Institution - 0004
    Stanford, California 94305, United States
  • Local Institution - 0042
    Torrance, California 90502, United States
  • Local Institution - 0340
    Newark, Delaware 19713, United States
  • Local Institution - 0075
    Gainesville, Florida 32610, United States
  • Local Institution - 0013
    Sarasota, Florida 34239, United States
  • Local Institution - 0024
    Tampa, Florida 33606, United States
  • Local Institution - 0015
    Augusta, Georgia 30912, United States
  • Local Institution - 0428
    Honolulu, Hawaii 96813, United States
  • Local Institution - 0293
    Chicago, Illinois 60612, United States
  • University of Illinois Hospital & Health Sciences System
    Chicago, Illinois 60612, United States
  • Local Institution - 0430
    Elk Grove Village, Illinois 60007, United States
  • Local Institution - 0382
    Rockford, Illinois 61114, United States
  • Local Institution - 0346
    Louisville, Kentucky 40202, United States
  • Local Institution - 0047
    New Orleans, Louisiana 70121, United States
  • Local Institution - 0420
    Baltimore, Maryland 21215, United States
  • Local Institution
    Boston, Massachusetts 02118, United States
  • Local Institution - 0236
    Boston, Massachusetts 02215, United States
  • Local Institution
    Detroit, Michigan 48201, United States
  • Local Institution - 0434
    Detroit, Michigan 48202, United States
  • Local Institution
    Detroit, Michigan 48235, United States
  • Local Institution - 0375
    Farmington Hills, Michigan 48334, United States
  • Local Institution
    Minneapolis, Minnesota 55415, United States
  • Local Institution
    Kansas City, Missouri 64111, United States
  • Local Institution
    Saint Louis, Missouri 63104, United States
  • Local Institution - 0294
    Saint Louis, Missouri 63110, United States
  • Local Institution - 0352
    Saint Louis, Missouri 63110, United States
  • Advanced Neurology Specialists PLLC
    Great Falls, Montana 59405, United States
  • Local Institution - 0276
    Camden, New Jersey 08103, United States
  • Local Institution - 0039
    New Brunswick, New Jersey 08901, United States
  • Local Institution - 0354
    Brooklyn, New York 11203, United States
  • Local Institution
    Buffalo, New York 14202, United States
  • Local Institution
    New York, New York 10016, United States
  • Local Institution - 0125
    New York, New York 10032, United States
  • Duke University Medical Center
    Butner, North Carolina 27509-1626, United States
  • Local Institution - 0043
    Chapel Hill, North Carolina 27599, United States
  • Local Institution - 0016
    Greensboro, North Carolina 27405, United States
  • Local Institution
    Winston-Salem, North Carolina 27157, United States
  • Local Institution - 0003
    Cleveland, Ohio 44106, United States
  • Local Institution - 0050
    Cleveland, Ohio 44195, United States
  • Local Institution - 0419
    Columbus, Ohio 43210, United States
  • Local Institution - 0218
    Oklahoma City, Oklahoma 73112, United States
  • Local Institution - 0022
    Portland, Oregon 97239-3011, United States
  • Local Institution - 0302
    Abington, Pennsylvania 19001, United States
  • Local Institution
    Allentown, Pennsylvania 18103-6381, United States
  • Local Institution
    Camp Hill, Pennsylvania 17011, United States
  • Local Institution - 0018
    Erie, Pennsylvania 16550-0001, United States
  • Local Institution - 0020
    Philadelphia, Pennsylvania 19104, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Local Institution - 0019
    York, Pennsylvania 17403, United States
  • Local Institution - 0041
    Columbia, South Carolina 29203, United States
  • Local Institution - 0009
    Nashville, Tennessee 37232-6307, United States
  • Local Institution - 0008
    Austin, Texas 78712, United States
  • Neurology Consultants of Dallas, PA
    Dallas, Texas 75321, United States
  • Local Institution
    Dallas, Texas 75390-88520, United States
  • University Medical center of El Paso
    El Paso, Texas 79905, United States
  • Local Institution - 0040
    Houston, Texas 77030, United States
  • Local Institution - 0093
    Houston, Texas 77030, United States
  • Local Institution - 0187
    Temple, Texas 76508, United States
  • Local Institution
    Richmond, Virginia 23298, United States
  • Local Institution
    Milwaukee, Wisconsin 53226, United States
  • Local Institution - 0100
    Adrogué, Buenos Aires B1846DSK, Argentina
  • Local Institution - 0063
    Caba, Buenos Aires C1199ABB, Argentina
  • Local Institution - 0076
    Caba, Buenos Aires C1428AQK, Argentina
  • Local Institution - 0067
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1180AAX, Argentina
  • Local Institution - 0237
    Lomas de Zamora, Buenos Aires 1832, Argentina
  • Local Institution - 0435
    Recoleta, Buenos Aires C1115AAB, Argentina
  • Local Institution
    Buenos Aires, 1437, Argentina
  • Local Institution - 0068
    Buenos Aires, C1425DND, Argentina
  • Local Institution
    Buenos Aires, C1425, Argentina
  • Local Institution
    Santa Fe, 3000, Argentina
  • Local Institution - 0329
    Randwick, New South Wales 2031, Australia
  • Local Institution - 0360
    Sydney, New South Wales 2170, Australia
  • Local Institution - 0287
    Southport, Queensland 4215, Australia
  • Local Institution - 0399
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0397
    Launceston, Tasmania 7250, Australia
  • Local Institution - 0358
    Clayton, Victoria 3168, Australia
  • Local Institution - 0281
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0315
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0184
    Klagenfurt Am Woerthersee, 9020, Austria
  • Local Institution
    St. Pölten, 3100, Austria
  • Local Institution - 0106
    Vocklabruck, 4840, Austria
  • Local Institution - 0273
    Wien, 1160, Austria
  • Local Institution - 0122
    Edegem, Antwerpen 2650, Belgium
  • Local Institution - 0196
    Brussel, Brussels 1090, Belgium
  • Local Institution - 0192
    Yvoir, Namur 5530, Belgium
  • Local Institution
    Brasschaat, 2930, Belgium
  • Local Institution - 0284
    Bruges, 8000, Belgium
  • Local Institution - 0427
    Brussels, 1020, Belgium
  • Local Institution - 0190
    Brussels, 1200, Belgium
  • Local Institution - 0305
    Bruxelles, 1070, Belgium
  • Local Institution - 0199
    Gent, 9000, Belgium
  • Local Institution - 0103
    Kortrijk, 8500, Belgium
  • Local Institution - 0098
    Leuven, 3000, Belgium
  • Local Institution - 0178
    Liege, 4000, Belgium

Showing the first 100 of 424 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Mar 2022, 38 months.

Results were first posted in Jun 2023, 1 year 2 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 38 months is above that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2018
First posted
Dec 6, 2018
StartActual
Jan 27, 2019
Primary completionActual
Mar 31, 2022
CompletionActual
Mar 31, 2022
Results first posted
Jun 12, 2023
Last update
Jun 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03766581
Collaborators
Janssen, LP
Responsible party
Sponsor
First posted
Dec 6, 2018
Start date
Jan 27, 2019
Primary completion
Mar 31, 2022
Completion
Mar 31, 2022
Results posted
Jun 12, 2023
Last update
Jun 12, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion